Meet The Team

NeuroSigma's research efforts are lead by an experienced team of doctors, scientists, and engineers.

Leadership

Colin P. Kealey, M.D

Founder & CEO

Ian A. Cook, M.D.

Chief Medical Officer

Vikas Gupta

Director of Engineering

Patrick Miller

Director of Operations

NeuroSigma's leadership is made up of experts in business management and the healthcare industry that have studied and conducted research at some of the most important institutions in the world. Together they provide extensive experience gained through years of creating and guiding successful companies and innovative medical research.

Our Partners and Supporters

The Monarch eTNS® System
The First FDA Cleared Device for Treating Pediatric ADHD.

The Monarch eTNS® System is indicated for the treatment of pediatric Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy in patients ages 7 through 12 years old who are not currently taking prescription ADHD medications.

The device is used for patient treatment by prescription only and is intended to be used in the home under the supervision of a caregiver during periods of sleep.

Learn More

Important Safety Information:

Indication: Monarch eTNS® System is indicated for treatment of pediatric ADHD as a monotherapy in patients ages 7 to 12 who are not currently on prescription ADHD medications. The device is for use during sleep under the supervision of a caregiver.

Contraindications: Not for use in patients with implanted pacemakers, neurostimulators, or metallic/electronic head implants. Do not use in children under 7.

Common side effects: Drowsiness, increased appetite, insomnia, teeth clenching, headache, fatigue. Rx Only. Please refer to the Instructions for Use or contact us for full safety information.”

For full Indication, Contraindications and Important Safety Information see the detailed labeling or contact Medical Affairs at (310) 479-3100.

References:

1. McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-label pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. Brain Stimulation. 2015;8:299-304.

2. McGough JJ, Sturm A, Cowen J, et al. Double-blind, sham-controlled, pilot study of trigeminal nerve stimulation for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2019;58(4):403-411.